Roche: positive data for lung cancer drug Tecentriq
(CercleFinance.com) - Roche has announced that the phase III IMpower010 study evaluating its Tecentriq (atezolizumab) versus best supportive care has achieved its primary endpoint of disease-free survival on an interim analysis.
Tecentriq showed a statistically significant improvement as an adjuvant therapy following surgery and chemotherapy in all randomised stage II-IIIA non-small cell lung cancer populations.
The data will be submitted to health authorities worldwide from now, including the US FDA and the European Medicines Agency, with it due to be presented at an upcoming medical meeting.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Tecentriq showed a statistically significant improvement as an adjuvant therapy following surgery and chemotherapy in all randomised stage II-IIIA non-small cell lung cancer populations.
The data will be submitted to health authorities worldwide from now, including the US FDA and the European Medicines Agency, with it due to be presented at an upcoming medical meeting.
Copyright (c) 2021 CercleFinance.com. All rights reserved.